TECENTRIQ Drug Use Surveillance(advanced or recurrent non-small cell lung cancer)

TECENTRIQ Drug Use Surveillance(advanced or recurrent non-small cell lung cancer) - TECENTRIQ Drug Use Surveillance(NSCLC)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000031978

Enrollment

1000

Registered

2018-04-17

Start date

2018-04-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients who are scheduled to receive TECENTRIQ at contracted institutions during this surveillance's enrollment period.

Exclusion criteria

Exclusion criteria: No criteria

Design outcomes

Primary

Measure	Time frame
The incidence of ADRs.	—

Secondary

Measure	Time frame
- The time of onset of ADRs. - The treatment status and outcome of ADRs. - The incidence of ADRs for each patient baseline characteristic.	—

Countries

Japan

Contacts

Public ContactAyaka Shimizu

Chugai Pharmaceutical Co. Ltd. Real world data science Dept.

shimizuayk@chugai-pharm.co.jp03-3273-0905

Outcome results